This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-25 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
==== MeSH D08.244.453 – cytochrome p-450 enzyme system ==== MeSH D08.244.453.040 – aryl hydrocarbon hydroxylases MeSH D08.244.453.040.050 – aniline hydroxylase MeSH D08.244.453.040.110 – benzopyrene hydroxylase MeSH D08.244.453.040.555 – cytochrome p-450 cyp1a1 MeSH D08.244.453.040.777 – cytochrome p-450 cyp1a2 MeSH D08.244.453.040.888 – cytochrome p-450 cyp2b1 MeSH D08.244.453.040.944 – cytochrome p-450 cyp2d6 MeSH D08.244.453.040.972 – cytochrome p-450 cyp2e1 MeSH D08.244.453.040.986 – cytochrome p-450 cyp3a MeSH D08.244.453.085 – camphor 5-monooxygenase MeSH D08.244.453.915 – steroid hydroxylases MeSH D08.244.453.915.050 – aldosterone synthase MeSH D08.244.453.915.099 – aromatase MeSH D08.244.453.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.244.453.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.244.453.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.244.453.915.720 – steroid 11-beta-hydroxylase MeSH D08.244.453.915.730 – steroid 12-alpha-hydroxylase MeSH D08.244.453.915.737 – steroid 16-alpha-hydroxylase MeSH D08.244.453.915.748 – steroid 17-alpha-hydroxylase MeSH D08.244.453.915.760 – steroid 21-hydroxylase MeSH D08.244.453.957 – trans-cinnamate 4-monooxygenase
The pharmacokinetic properties of sitagliptin and vildagliptin appear unaffected by age, sex or BMI. Clinical researches have shown that sitagliptin and vildagliptin do not have the side effects that tend to follow type 2 diabetes treatment, e.g. weight gain and hyperglycemia, but however, other side effects have been observed, including upper respiratory tract infections, sore throat and diarrhea.
== Operation == In an ion-to-photon detector, a photomultiplier tube is coated with a layer of scintillator compound, such as Rhodamine B or CsI. When the ions pass through the mass analyzer of the spectrometer, they strike the scintillator compound and cause the release of photons. These photons are then detected by the photomultiplier tube. A conversion dynode, such as a microchannel plate can also be used between the ion beam and the scintillator to increase the signal. An MCP, when struck by an ion, will release electrons which then strike the scintillator.
Sources: en.wikipedia.org
=== First Nations relations === In March 2021, Ford publicly accused MPP Sol Mamakwa of "jumping the line" to receive his second dose of a COVID-19 vaccine, despite being eligible to receive it. Mamakwa went to his riding to receive the vaccine as an attempt to prevent vaccine hesitancy amongst his constituents. On Thursday, March 11, 2021, Ford apologised for his remark and later said he "got a little personal" when throwing the accusation at Mamakwa. Mamakwa did not say that he accepted Ford's apology but stated that he appreciated the call from Ford. In September 2021, an Ontario judge issued an injunction on mining in Wiisinin Zaahgi'igan (an area sacred to the Ginoogaming First Nation peoples). The judge ruled that the Ontario government did not consult with the Ginoogaming as is their constitutional duty. Ford's 2024 Reducing Gridlock, Saving you Time Act removed the requirement for future Indigenous consultation for the upcoming Highway 413 in a possible contravention of Ontario's Environmental Assessment Act. In addition, the Indigenous consultation period for the bill was only 30 days, decried by the regional chief as 'too short'. Many Indigenous and environmental advocacy groups opposed his government's Protecting Ontario by Unleashing Our Economy Act, or Bill 5, which gives Ford's cabinet the ability to create special economic zones and exempt companies or projects from having to comply with any provincial law, provincial regulation or municipal bylaw. Ford also apologized for saying that First Nations "keep coming hat in hand" for government money in June 2025.
== Method principle == Before the introduction of the first automated cell counters, hematologists were referred to manual cell count under the microscope. The Celloscope method for automated counting of blood cells was described in an article by Öhlin in 1958. In the described method, cells in a saline (conductive) solution are allowed to pass through a capillary with a length and diameter corresponding to the size of blood cells. At the same time, an electric current passes the capillary, and each cell then gives rise to an electric pulse through the increase in resistance that it causes in the electric circuit. The number of pulses is recorded and corresponds to the number of cells in a certain volume. Diluting the blood sample to a sufficient extent for the distance between the cells when passing through the capillary to be greater than the dimension of the cells and capillary ensures that each cell is counted individually. As cells are counted in an absolute volume of the suspension, the number of cells in mm3 of whole blood can be calculated using the dilution factor. The described automated Celloscope cell count method enabled an improved accuracy compared with manual examination by microscopy, while decreasing manual work for the operator. The method allows 50 000 cells to be counted in about 45 seconds, with high accuracy. The Celloscope counter was also equipped with a discriminator, or electrical threshold, which allows only pulses above a certain size to be counted, enabling different blood cells to be counted.
== Reactions == Compared to other heteroallenes, carbodiimides are very weak electrophiles and only react with nucleophiles in the presence of catalysts, such as acids. In this way, guanidines can be prepared. As weak bases, carbodiimides bind to Lewis acids to give adducts.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.